Brief: Ascletis Pharma Says IND Filing Of Second FASN Inhibitor ASC60 Was Accepted By China NMPA
26/01/2022 10:32
Jan 26 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ANNOUNCES IND FILING OF ITS SECOND FASN INHIBITOR ASC60
FOR
ADVANCED SOLID TUMORS ACCEPTED BY CHINA NMPA
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026